Optimizing the Management of Squamous Cell Carcinoma of the Head and Neck With Immunotherapeutic Strategies
Drs Weiss and Burtness discuss the latest immunotherapeutic strategies in the management of head and neck cancers.
The goal of this initiative is to update clinicians about the evidence base on cancer immunotherapies, including the role of biomarkers, and provide guidance on applying these data to improve performance and increase confidence in integrating immunotherapeutic regimens into practice.
This activity is intended for oncologists, otolaryngologists, and pathologists on the SCCHN care team.
Learning Objectives:
- Have increased knowledge regarding the
- Current treatment paradigm for metastatic SCCHN
- Key clinical trial data evaluating immune-modulating therapies for the treatment of SCCH
- Demonstrate greater confidence in their ability to
- Integrate key clinical trial data into practice for the treatment of patients with SCCHN
Approximate Time to Complete: 30 minutes
Credit Available: February 24, 2022 - February 24, 2023
Developed through a partnership between SITC and Medscape.
 |
|
Additional Resources for Clinicans from SITC:
- Have increased knowledge regarding the current treatment paradigm for metastatic SCCHN.
- Demonstrate greater confidence in their ability to integrate key clinical trial data into practice for the treatment of patients with SCCHN.
- Have increased knowledge regarding the key clinical trial data evaluating immune-modulating therapies for the treatment of SCCHN.
AMA PRA Category 1 Credit(s)™: 0.50
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.50